Janux Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in novel immunotherapies, has officially named William Go, M.D., Ph.D., as its new Chief Medical Officer (CMO). Dr. Go succeeds Dr. Zachariah McIver, who is departing the company to pursue other opportunities.
Professional expertise and background
Dr. William Go brings over two decades of experience in hematology and oncology, having led programs through early clinical stages, pivotal trials, and successful global regulatory approvals for first-in-class launches.
-
Previous achievements: Prior to joining Janux, he served as CMO at A2 Biotherapeutics. Notably, during his tenure at Kite Pharma, he headed the pivotal ZUMA-1 trial, which provided the clinical foundation for the FDA and EMA approvals of YESCARTA.
-
Leadership at major firms: He also held senior roles at Gilead Sciences and Amgen, where he contributed to the global label expansion of Vectibix and the advancement of next-generation sequencing strategies for colorectal cancer.
Strategic vision
This appointment comes as Janux enters a critical new phase, characterized by the increasing complexity of its clinical and regulatory efforts. David Campbell, CEO of Janux, emphasized that Dr. Go’s combination of development experience and launch execution will strengthen the organization as it scales.
In related news, Janux recently announced an exclusive worldwide licensing agreement with Bristol Myers Squibb (BMS) to develop a novel, tumor-activated therapeutic.